Perjeta trial a setback for Roche, not a disaster: Novasecta managing partner

John Rountree, managing partner at Novasecta, discusses the fallout of a disappointing breast cancer drug trial for pharmaceutical firm Roche.

from Mergers and Acquisitions http://ift.tt/2qX1bqe